Search research articles
Contact Us
Filters
Showing results (11-20 of 32) with videos related to
Page
of 4
Sort By:
Journal of Clinical Medicine
|
March 4, 2020
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
Markus Kieler, Matthias Unseld, Daniela Bianconi, et al.
Cancer Management and Research
|
August 16, 2021
Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
Sukirthini Balendran-Braun, Markus Kieler, Sandra Liebmann-Reindl, et al.
Clinical Colorectal Cancer
|
July 26, 2018
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
Matthias Unseld, Magdalena Drimmel, Alexander Siebenhüner, et al.
Palliative Medicine
|
February 21, 2022
C-reactive protein and white blood cell count are adverse prognostic markers for patients with advanced cancer on parenteral nutrition in a palliative care unit setting: A retrospective cohort study
Markus Kieler, Paul Kössler, Matija Milovic, et al.
Nutrients
|
February 26, 2022
Kidney Function Worsening Is Linked to Parenteral-Nutrition-Dependent Survival in Palliative Care Patients
Lea Kum, Alexander Friedrich, Markus Kieler, et al.
Journal of Clinical Medicine
|
June 11, 2020
Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
Matthias Unseld, Sebastian Fischöder, Mathias Jachs, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
April 4, 2026
PET/MRI with <sup>89</sup>Zr-labelled antibodies provides insights into altered antibody pharmacokinetics in the chick embryo model
Katarína Benčurová, Daniel Gündel, Markus Kieler, et al.
Therapeutic Advances in Medical Oncology
|
September 14, 2020
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
Daniela Bianconi, Merima Herac, Florian Posch, et al.
Translational Oncology
|
September 25, 2018
SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
Daniela Bianconi, Merima Herac, Daniel Spies, et al.
Scientific Reports
|
July 9, 2017
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
Daniela Bianconi, Gerwin Heller, Daniel Spies, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 32) with videos related to
Sort By:
Page
of 4
Journal of Clinical Medicine
|
March 4, 2020
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
Markus Kieler, Matthias Unseld, Daniela Bianconi, et al.
Cancer Management and Research
|
August 16, 2021
Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
Sukirthini Balendran-Braun, Markus Kieler, Sandra Liebmann-Reindl, et al.
Clinical Colorectal Cancer
|
July 26, 2018
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
Matthias Unseld, Magdalena Drimmel, Alexander Siebenhüner, et al.
Palliative Medicine
|
February 21, 2022
C-reactive protein and white blood cell count are adverse prognostic markers for patients with advanced cancer on parenteral nutrition in a palliative care unit setting: A retrospective cohort study
Markus Kieler, Paul Kössler, Matija Milovic, et al.
Nutrients
|
February 26, 2022
Kidney Function Worsening Is Linked to Parenteral-Nutrition-Dependent Survival in Palliative Care Patients
Lea Kum, Alexander Friedrich, Markus Kieler, et al.
Journal of Clinical Medicine
|
June 11, 2020
Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
Matthias Unseld, Sebastian Fischöder, Mathias Jachs, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
April 4, 2026
PET/MRI with <sup>89</sup>Zr-labelled antibodies provides insights into altered antibody pharmacokinetics in the chick embryo model
Katarína Benčurová, Daniel Gündel, Markus Kieler, et al.
Therapeutic Advances in Medical Oncology
|
September 14, 2020
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
Daniela Bianconi, Merima Herac, Florian Posch, et al.
Translational Oncology
|
September 25, 2018
SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
Daniela Bianconi, Merima Herac, Daniel Spies, et al.
Scientific Reports
|
July 9, 2017
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
Daniela Bianconi, Gerwin Heller, Daniel Spies, et al.
Page
of 4